Brainstorm Cell Ther (BCLI) 7.50 $BCLI
Stocks in Whipsaw to Start 2015 as Weak Manufacturing Blunts Optimism
at The Street - Fri Jan 02, 3:20PM CST
Wall Street will likely excuse the bumpy start to the year as traders focus on a busy week ahead.
MU: 34.75 (-0.26), PSMT: 89.80 (-1.42), MON: 119.74 (+0.27), SYNA: 64.25 (-4.59), GBX: 53.96 (+0.23), WYNN: 146.89 (-1.87), LVS: 56.30 (-1.86), FDO: 78.89 (-0.32), HNR: 0.93 (-0.88), MGM: 21.02 (-0.36), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11), BLDP: 1.83 (-0.15), AYI: 139.88 (-0.19), AA: 15.88 (+0.09), BBBY: 76.73 (+0.56), SONC: 27.55 (+0.32)
Rite Aid and Petrobras are big market movers
AP - Fri Jan 02, 3:11PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
BLDP: 1.83 (-0.15), BLD.TO: 2.15 (-0.22), GNTX: 17.93 (-18.20), HNR: 0.93 (-0.88), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11)
Stocks Yo-Yo as U.S. Manufacturing Activity Hits Six-Month Low
at The Street - Fri Jan 02, 1:39PM CST
Indications of weakness in manufacturing serve to reverse the S&P 500 which had jumped at the open.
BLDP: 1.83 (-0.15), SYNA: 64.25 (-4.59), WYNN: 146.89 (-1.87), LVS: 56.30 (-1.86), MGM: 21.02 (-0.36), HNR: 0.93 (-0.88), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 11:50AM CST
JBSS: 41.09 (-4.41), MELA: 1.61 (+0.41), SYRX: 2.04 (unch), NRX: 10.68 (-2.67), NKA: 3.67 (+0.71), PRTK: 34.54 (-4.01), JOB: 1.66 (+0.45), HNR: 0.93 (-0.88), BCLI: 7.50 (+2.74), QTWW: 2.42 (+0.33), CHNR: 2.77 (+0.41), PWRD: 19.25 (+3.49), CJJD: 2.56 (-0.34), WTW: 21.53 (-3.31), LOCK: 15.89 (-2.62), MDXG: 9.74 (-1.79), GNI: 10.77 (-3.13), ATEA: 2.02 (+0.27), EXEL: 1.65 (+0.21)
Stocks Turn Negative as U.S. Manufacturing Slides to Six-Month Low
at The Street - Fri Jan 02, 9:49AM CST
The stock market rallied in the first trading day of the year as positive sentiment carried over into 2015.
BLDP: 1.83 (-0.15), BBBY: 76.73 (+0.56), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11)
Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today
at The Street - Fri Jan 02, 8:53AM CST
Shares of Brainstorm Cell Therapeutics (BCLI) soared more than 75% to a 52-week high of $8.47 on Friday ahead of the biotech company's data release on Monday.
BCLI: 7.50 (+2.74)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 1.03 (+0.01), BLDP: 1.83 (-0.15), PBR: 6.76 (-0.54), LNCO: 11.50 (+1.13), KITE: 60.61 (+2.94), NRX: 10.68 (-2.67), LINE: 11.35 (+1.22), PWRD: 19.25 (+3.49), BCLI: 7.50 (+2.74), CUR: 2.81 (+0.09)
Brainstorm up big premarket on NurOwn results in ALS
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 7:27AM CST
BCLI: 7.50 (+2.74)
Stock Futures Point to Positive Open in First Session of 2015
at The Street - Fri Jan 02, 7:12AM CST
Stock futures look to kick off 2015 with gusto on the first trading day of the year.
BBBY: 76.73 (+0.56), LINE: 11.35 (+1.22), BCLI: 7.50 (+2.74)
Happy New 'Investing' Year: Complementary Reports on Daily Journal, Trina Solar, Cytokinetics, BrainStorm, and Resolute
PR Newswire - Fri Jan 02, 7:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Daily Journal (NASDAQ: DJCO), Trina Solar (NYSE: TSL), Cytokinetics (NASDAQ: CYTK), BrainStorm (NASDAQ: BCLI), and Resolute (NYSE: REN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CYTK: 7.37 (-0.64), REN: 1.18 (-0.14), TSL: 9.53 (+0.27), DJCO: 240.00 (-23.01), BCLI: 7.50 (+2.74)
Brainstorm Cell Therapeutics (BCLI) Stock Rises Today Ahead of ALS Treatment Trial Data Release
at The Street - Wed Dec 31, 9:36AM CST
Shares of Brainstorm Cell Therapeutics (BCLI) surged on higher-than-average volume in morning trading Wednesday ahead of the biotech company's data release on Monday.
BCLI: 7.50 (+2.74)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 2.59 (unch), PSTI: 2.69 (+0.19), NBS: 3.73 (-0.04), STEM: 1.03 (+0.09), BCLI: 7.50 (+2.74), CUR: 2.81 (+0.09)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.40 (-0.04), TEVA: 56.22 (-1.29), ITCI: 17.57 (-0.08), BCLI: 7.50 (+2.74), OMER: 25.01 (+0.23), NVS: 92.25 (-0.41)
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office
PR Newswire - Mon Dec 15, 5:45AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant of approximately $1.1 million from Israel's Office of the Chief Scientist (OCS). This is the eighth year that BrainStorm has been in receipt of grant support from the Office of the Chief Scientist, which is part of the Ministry of Trade and Industry Program to support innovative technologies in Israel. The funds will support the development NurOwn(TM), BrainStorm's innovative mesenchymal stem cell-based platform for treating neurodegenerative diseases including BrainStorm's phase 2 clinical program in amyotrophic lateral sclerosis (ALS).
BCLI: 7.50 (+2.74)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 342.01 (+2.56), KNMD: (), GSK: 42.37 (-0.37), BCLI: 7.50 (+2.74), CBMG: 13.79 (+0.88), CUR: 2.81 (+0.09)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 5.14 (+0.11), AST: 3.30 (+0.06), CBMG: 13.79 (+0.88), BCLI: 7.50 (+2.74), NVS: 92.25 (-0.41), CELGZ: 3.15 (unch)
BrainStorm Cell Therapeutics' (BCLI) CEO Tony Fiorino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:35AM CST
BCLI: 7.50 (+2.74)
BrainStorm Cell Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:01AM CST
BCLI: 7.50 (+2.74)
Stocks in Whipsaw to Start 2015 as Weak Manufacturing Blunts Optimism
at The Street - Fri Jan 02, 3:20PM CST
Wall Street will likely excuse the bumpy start to the year as traders focus on a busy week ahead.
MU: 34.75 (-0.26), PSMT: 89.80 (-1.42), MON: 119.74 (+0.27), SYNA: 64.25 (-4.59), GBX: 53.96 (+0.23), WYNN: 146.89 (-1.87), LVS: 56.30 (-1.86), FDO: 78.89 (-0.32), HNR: 0.93 (-0.88), MGM: 21.02 (-0.36), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11), BLDP: 1.83 (-0.15), AYI: 139.88 (-0.19), AA: 15.88 (+0.09), BBBY: 76.73 (+0.56), SONC: 27.55 (+0.32)
Rite Aid and Petrobras are big market movers
AP - Fri Jan 02, 3:11PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
BLDP: 1.83 (-0.15), BLD.TO: 2.15 (-0.22), GNTX: 17.93 (-18.20), HNR: 0.93 (-0.88), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11)
Stocks Yo-Yo as U.S. Manufacturing Activity Hits Six-Month Low
at The Street - Fri Jan 02, 1:39PM CST
Indications of weakness in manufacturing serve to reverse the S&P 500 which had jumped at the open.
BLDP: 1.83 (-0.15), SYNA: 64.25 (-4.59), WYNN: 146.89 (-1.87), LVS: 56.30 (-1.86), MGM: 21.02 (-0.36), HNR: 0.93 (-0.88), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 11:50AM CST
JBSS: 41.09 (-4.41), MELA: 1.61 (+0.41), SYRX: 2.04 (unch), NRX: 10.68 (-2.67), NKA: 3.67 (+0.71), PRTK: 34.54 (-4.01), JOB: 1.66 (+0.45), HNR: 0.93 (-0.88), BCLI: 7.50 (+2.74), QTWW: 2.42 (+0.33), CHNR: 2.77 (+0.41), PWRD: 19.25 (+3.49), CJJD: 2.56 (-0.34), WTW: 21.53 (-3.31), LOCK: 15.89 (-2.62), MDXG: 9.74 (-1.79), GNI: 10.77 (-3.13), ATEA: 2.02 (+0.27), EXEL: 1.65 (+0.21)
Stocks Turn Negative as U.S. Manufacturing Slides to Six-Month Low
at The Street - Fri Jan 02, 9:49AM CST
The stock market rallied in the first trading day of the year as positive sentiment carried over into 2015.
BLDP: 1.83 (-0.15), BBBY: 76.73 (+0.56), BCLI: 7.50 (+2.74), RAD: 7.63 (+0.11)
Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today
at The Street - Fri Jan 02, 8:53AM CST
Shares of Brainstorm Cell Therapeutics (BCLI) soared more than 75% to a 52-week high of $8.47 on Friday ahead of the biotech company's data release on Monday.
BCLI: 7.50 (+2.74)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 1.03 (+0.01), BLDP: 1.83 (-0.15), PBR: 6.76 (-0.54), LNCO: 11.50 (+1.13), KITE: 60.61 (+2.94), NRX: 10.68 (-2.67), LINE: 11.35 (+1.22), PWRD: 19.25 (+3.49), BCLI: 7.50 (+2.74), CUR: 2.81 (+0.09)
Brainstorm up big premarket on NurOwn results in ALS
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 7:27AM CST
BCLI: 7.50 (+2.74)
Stock Futures Point to Positive Open in First Session of 2015
at The Street - Fri Jan 02, 7:12AM CST
Stock futures look to kick off 2015 with gusto on the first trading day of the year.
BBBY: 76.73 (+0.56), LINE: 11.35 (+1.22), BCLI: 7.50 (+2.74)
Happy New 'Investing' Year: Complementary Reports on Daily Journal, Trina Solar, Cytokinetics, BrainStorm, and Resolute
PR Newswire - Fri Jan 02, 7:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Daily Journal (NASDAQ: DJCO), Trina Solar (NYSE: TSL), Cytokinetics (NASDAQ: CYTK), BrainStorm (NASDAQ: BCLI), and Resolute (NYSE: REN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CYTK: 7.37 (-0.64), REN: 1.18 (-0.14), TSL: 9.53 (+0.27), DJCO: 240.00 (-23.01), BCLI: 7.50 (+2.74)
Brainstorm Cell Therapeutics (BCLI) Stock Rises Today Ahead of ALS Treatment Trial Data Release
at The Street - Wed Dec 31, 9:36AM CST
Shares of Brainstorm Cell Therapeutics (BCLI) surged on higher-than-average volume in morning trading Wednesday ahead of the biotech company's data release on Monday.
BCLI: 7.50 (+2.74)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 2.59 (unch), PSTI: 2.69 (+0.19), NBS: 3.73 (-0.04), STEM: 1.03 (+0.09), BCLI: 7.50 (+2.74), CUR: 2.81 (+0.09)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.40 (-0.04), TEVA: 56.22 (-1.29), ITCI: 17.57 (-0.08), BCLI: 7.50 (+2.74), OMER: 25.01 (+0.23), NVS: 92.25 (-0.41)
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office
PR Newswire - Mon Dec 15, 5:45AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant of approximately $1.1 million from Israel's Office of the Chief Scientist (OCS). This is the eighth year that BrainStorm has been in receipt of grant support from the Office of the Chief Scientist, which is part of the Ministry of Trade and Industry Program to support innovative technologies in Israel. The funds will support the development NurOwn(TM), BrainStorm's innovative mesenchymal stem cell-based platform for treating neurodegenerative diseases including BrainStorm's phase 2 clinical program in amyotrophic lateral sclerosis (ALS).
BCLI: 7.50 (+2.74)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 342.01 (+2.56), KNMD: (), GSK: 42.37 (-0.37), BCLI: 7.50 (+2.74), CBMG: 13.79 (+0.88), CUR: 2.81 (+0.09)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 5.14 (+0.11), AST: 3.30 (+0.06), CBMG: 13.79 (+0.88), BCLI: 7.50 (+2.74), NVS: 92.25 (-0.41), CELGZ: 3.15 (unch)
BrainStorm Cell Therapeutics' (BCLI) CEO Tony Fiorino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:35AM CST
BCLI: 7.50 (+2.74)
BrainStorm Cell Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:01AM CST
BCLI: 7.50 (+2.74)
